Clinical trials: Clear Cell Renal Cancer
Non-Clear Cell Renal Cell Carcinoma
Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma
This study will compare benmelstobart plus anlotinib with sunitinib as the first treatment for adults with advanced non-clear cell renal cell carcinoma, a type of kidney cancer.
- Trial name
- NCT07881900
- Testing
- Benmelstobart, Anlotinib, Sunitinib
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Renal Cell
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have…
- Trial name
- CheckMate 914 (NCT03138512)
- Testing
- nivolumab, ipilimumab
- Where
- 200 sites in United States, Argentina and 23 more
- Volunteers
- 1,641 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
RATIONALE: Learning about the amount of information on fertility and infertility by patients before they received treatment for cancer in a comprehensive cancer center may help doctors plan the best treatment.
- Trial name
- NCT01295463
- Testing
- questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut Català d'Oncologia
Triple Negative Breast Cancer, Uterine Cervical Cancer
Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy
The aim of the study is to evaluate the response to four schemes of treatment with novel diagnostic tools - Immuno-PET and proteomics as well as standard imaging (magnetic resonsonce imaging and computed tomography).
- Conditions
- Triple Negative Breast Cancer, Uterine Cervical Cancer, Uterine Corpus Cancer, Malignant Melanoma
- Trial name
- INTROSPECTION (NCT06976021)
- Testing
- Baseline 89-Zr Pembrolizumab Immuno PET-CT, Proteomic assay, Follow-up 89-Zr Pembrolizumab Immuno PET-CT
- Volunteers
- 60 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Immunotherapy, Cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
- Conditions
- Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- ELEPHAS-02 (NCT05520099)
- Testing
- Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
- Where
- 12 sites in United States
- Volunteers
- 416 people
- Sponsor
- Elephas
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in…
- Trial name
- NCT01684397
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pazopanib Hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Roswell Park Cancer Institute
Renal Cell Carcinoma
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
This is a single-arm, multicenter, phase 2 study of lenvatinib in combination with pembrolizumab (lenvatinib 20 mg/day + pembrolizumab 200mg q3weeks) in subjects with unresectable advanced or metastatic non-clear cell renal…
- Trial name
- NCT04267120
- Testing
- Lenvatinib, Pembrolizumab, Research blood collection
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Chromophobe Renal Cell Carcinoma, Clear Cell Papillary Renal Tumor
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors.
- Conditions
- Chromophobe Renal Cell Carcinoma, Clear Cell Papillary Renal Tumor, Clear Cell Renal Cell Carcinoma, Kidney Oncocytoma
- Trial name
- NCT06339138
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 589 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Advanced Kidney Cancer, Kidney Cancer
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
This is a single arm, multi-centre (via Big Ten Cancer Research Consortium) phase Ib/II study of patients treated with durvalumab 1500 mg IV q 4 weeks in combination with guadecitabine at the recommended phase 2 dose…
- Conditions
- Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT03308396
- Testing
- Guadecitabine, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- Ajjai Alva, MD
Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma
MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
This study is being carried out to see if the drugs MEDI4736, Savolitinib and Tremelimumab can be used alone or in combination to reduce the size of tumours in patients with kidney cancer.
- Trial name
- CALYPSO (NCT02819596)
- Testing
- Savolitinib, MEDI4736, Tremelimumab
- Where
- United Kingdom
- Volunteers
- 69 people
- Sponsor
- Queen Mary University of London
Renal Cell Carcinoma
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.
- Trial name
- NCT01354431
- Testing
- nivolumab
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 168 people
- Sponsor
- Bristol-Myers Squibb
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
This phase I trial studies the side effects and best dose of autologous dendritic cells in treating patients with metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01826877
- Testing
- AdGMCAIX-transduced autologous dendritic cells, therapeutic autologous dendritic cells, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
This phase I trial tests the safety, side effects, best dose, and effectiveness of CBM588 in combination with nivolumab and ipilimumab in treating patients with kidney cancer that may have spread from where it first started to…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- NCT06399419
- Testing
- Biospecimen Collection, Bone Scan, CBM588 Capsules
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Osel, Inc.
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of pembrolizumab combined with axitinib as neoadjuvant therapy for locally advanced non-metastatic clear cell renal cell carcinoma.
- Trial name
- PANDORA (NCT04995016)
- Testing
- Pembrolizumab, Axitinib
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tianjin Medical University Second Hospital
Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Trial name
- NCT07195916
- Testing
- INCA036873
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 280 people
- Sponsor
- Incyte Corporation
Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or…
- Trial name
- NCT05363631
- Testing
- Selenomethionine (SLM), Axitinib, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fernando Maciel Barbosa
Renal Cell Carcinoma
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in ccRCC.
- Trial name
- NCT06049030
- Testing
- HS-10516
- Volunteers
- 190 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell…
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
- Trial name
- NCT07300241
- Testing
- NEO-811
- Where
- 14 sites in United States
- Volunteers
- 30 people
- Sponsor
- Neomorph, Inc
Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
TITAN RCC (0216-ASG) is a Phase 2, open-label study of nivolumab monotherapy with additional nivolumab/ipilimumab "boost" cycles in previously untreated and pretreated (2nd line), advanced or metastatic renal cell carcinoma…
- Trial name
- TITAN-RCC (NCT02917772)
- Testing
- Nivolumab/Ipilimumab
- Where
- 35 sites in Austria, Belgium and 6 more
- Volunteers
- 200 people
- Sponsor
- AIO-Studien-gGmbH